Welcome to our dedicated page for Coya Therapeutics news (Ticker: COYA), a resource for investors and traders seeking the latest updates and insights on Coya Therapeutics stock.
Coya Therapeutics, Inc. (NASDAQ: COYA) is a clinical-stage biotechnology company headquartered in Houston, Texas, with news flow centered on its regulatory T cell (Treg)–focused pipeline for neurodegenerative and inflammation-driven diseases. Company updates frequently highlight progress with COYA 302, an investigational proprietary biologic combination of low-dose interleukin-2 (LD IL-2) and CTLA-4 Ig, and COYA 303, an investigational combination of LD IL-2 and a GLP-1 receptor agonist.
Investors following COYA news can expect regular coverage of clinical trial milestones, including the Phase 2 ALSTARS Trial of COYA 302 in amyotrophic lateral sclerosis (ALS). Coya has announced key events such as FDA acceptance of its IND for COYA 302 in ALS, Health Canada’s acceptance of a Clinical Trial Application, initiation and dosing of patients in the ALSTARS Trial, and milestone payments received under its Development and License Agreement with Dr. Reddy’s Laboratories Ltd.
News items also describe regulatory developments for frontotemporal dementia (FTD), including FDA acceptance of an IND for COYA 302 in FTD and results from an investigator-initiated open-label study of low-dose IL-2 and CTLA4-Ig in FTD patients. Additional releases cover preclinical data for COYA 303 in an in vivo model of systemic and neurologic inflammation, corporate financing activities such as an upsized public offering of common stock, and quarterly financial results and corporate updates.
This COYA news page aggregates these disclosures so readers can review clinical, regulatory, scientific, and financing announcements in one place. For those tracking Treg-based approaches to ALS, FTD, Alzheimer’s disease, and related conditions, the news stream provides direct access to Coya’s reported data, trial status updates, and key corporate events over time.
Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotech company specializing in regulatory T cell (Treg) function enhancement for neurodegenerative disorders, has announced its participation in two major investor conferences in September 2025.
CEO Arun Swaminathan will present at the H.C. Wainwright Global Investment Conference on September 10 at 10 am ET at the Lotte New York Palace Hotel. The company will also attend the Lake Street Capital Markets Best Ideas Growth Conference on September 11 at The Yale Club of New York City. Management will be available for one-on-one meetings at both events.
A webcast of the presentation will be available on the company's website for 90 days.Coya Therapeutics (NASDAQ:COYA) has received FDA acceptance of its Investigational New Drug (IND) application for COYA 302, a proprietary immunomodulatory biologic combination therapy for treating Amyotrophic Lateral Sclerosis (ALS). The acceptance enables the company to proceed with a Phase 2 multicenter, double-blind, placebo-controlled clinical study to evaluate the treatment's efficacy and safety.
The milestone triggers a $4.2 million payment to Coya from its partner Dr. Reddy's Laboratories (DRL). The development represents a significant step in Coya's partnership with DRL to advance potential treatments for ALS patients.
Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotech company focused on regulatory T cell enhancement for neurodegenerative disorders, reported Q2 2025 financial results and corporate updates. The company ended Q2 with $29.8 million in cash and posted a net loss of $6.1 million, wider than the $2.9 million loss in Q2 2024.
Key developments include the FDA submission for COYA 302 Phase 2 trial in ALS patients, with a decision expected by August 29, 2025. Upon IND acceptance and first patient dosing, Coya will receive $8.4 million in milestone payments from Dr. Reddy's Laboratories. The company also secured a U.S. patent for a stable ready-to-use liquid IL-2 formulation and plans to submit an IND for Frontotemporal Dementia by year-end.
Coya Therapeutics (NASDAQ: COYA) has announced the publication of a significant research study examining the relationship between inflammation, oxidative stress, and Parkinson's Disease (PD) progression. The study, partially funded by Coya and published in Frontiers of Immunology, reveals important findings about immune dysfunction in PD pathogenesis.
The research demonstrates that peripheral blood monocytes from PD patients show distinct inflammatory patterns compared to healthy controls, with key findings including: upregulation of pro-inflammatory cytokines (IL-6 and IL-1b), increased expression of chemokine receptor CCR2, and varying levels of oxidative stress markers throughout disease progression.
The company is developing COYA 302, a dual immunomodulatory treatment designed to enhance regulatory T cell (Treg) function and suppress inflammation produced by activated monocytes and macrophages. This approach aligns with the study's findings regarding the role of peripheral inflammation in PD pathophysiology.
Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotech company focused on developing biologics for regulatory T cell function enhancement, has announced its participation in the upcoming BTIG Virtual Biotechnology Conference scheduled for July 29-30, 2025.
Interested parties can schedule one-on-one meetings with Coya's management team through their BTIG representatives.
Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotech company focused on developing biologics for regulatory T cell function enhancement, announces its participation in the H.C. Wainwright 3rd Annual BioConnect Conference on May 20, 2025. CEO Arun Swaminathan will engage in a fireside chat at 12:30pm ET at the Nasdaq World Headquarters in New York City.
The presentation will be available via webcast, with management offering one-on-one meeting opportunities. The webcast will be accessible through Coya's website and remain available for 90 days after the event.
Coya Therapeutics (NASDAQ: COYA), a clinical-stage biotech company focused on developing biologics for regulatory T cell function enhancement, has announced its participation in two upcoming conferences in May 2025. The company's leadership, including CEO Dr. Arun Swaminathan and CFO David Snyder, will be available for one-on-one meetings with registered investors at:
1. The D. Boral Capital Inaugural Global Conference on May 14, 2025, at The Plaza Hotel in New York
2. The Mizuho Neuro & Opthalmology Summit from May 20-21, 2025, at the Park Lane Hotel in New York
FAQ
What is the current stock price of Coya Therapeutics (COYA)?
What is the market cap of Coya Therapeutics (COYA)?
